Only pay if approved·Free shipping·Cancel anytime·Provider supervised·HIPAA secure

Provider-prescribed treatments. Subject to medical evaluation. Medications are dispensed by licensed U.S. pharmacies.

Back to Blog
GLP-1 / Weight Loss
📚 Informational 5/19/2026 7 min readBy EdenRx Medical Team

GLP-1 Weight Loss Statistics and Research Summary 2025

GLP-1 Weight Loss Statistics and Research Summary 2025

Ready to find out if you may qualify?

No payment required to start · Takes less than 60 seconds · Only pay if approved

Check Your Eligibility Free
No Payment Required Response Within 24h Built from Eden Med Spa

Key Takeaways

  • 1GLP-1 receptor agonists may support average weight reductions of 15–22% of body weight in eligible adults, based on 2025 clinical trial data — though individual results will always vary.
  • 22025 guidelines from leading obesity medicine organizations now formally recognize GLP-1 therapy as a first-line option for adults with obesity or overweight with related health conditions.
  • 3EdenRx offers provider-reviewed GLP-1 weight loss programs for eligible patients in Florida and New York through a transparent, accessible telehealth model with a free starting assessment.

Clinical research through 2025 consistently shows that GLP-1 receptor agonists may support significant body weight reduction in eligible adults when combined with lifestyle modifications, with some trials reporting average losses of 15–22% of total body weight over 68–72 weeks. If you are exploring medically supervised options, understanding the current GLP-1 weight loss statistics 2025 can help you have a more informed conversation with a licensed provider.

Ready to find out if you qualify? Start Free Assessment — No payment required.


What Are GLP-1 Receptor Agonists and How Do They Work?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed to manage type 2 diabetes. They work by mimicking a naturally occurring hormone that signals the brain to reduce appetite, slows gastric emptying, and helps regulate blood sugar. Over time, researchers and clinicians began observing meaningful weight loss as a secondary effect — a finding that has since become the centerpiece of numerous dedicated obesity trials.

Medications in this class include semaglutide and tirzepatide, among others. These agents are now among the most prescribed weight-related therapies in the United States. Through programs like the EdenRx GLP-1 Weight Loss Program, eligible patients in Florida and New York may access these treatments under the guidance of licensed, provider-reviewed care — though individual results will always vary.


Key GLP-1 Weight Loss Statistics 2025: What the Data Shows

The STEP trial series, which evaluated weekly semaglutide 2.4 mg injections, reported that participants lost an average of approximately 15% of their body weight over 68 weeks compared to roughly 2.4% in the placebo group. More recent 2024–2025 real-world data published in peer-reviewed journals has echoed these findings, suggesting that GLP-1 therapies may produce outcomes closer to surgical weight loss interventions than any previous non-surgical option.

Tirzepatide data from the SURMOUNT trials has been equally compelling, with some arms of the study reporting average weight reductions of up to 22.5% of body weight in adults with obesity but without diabetes. These GLP-1 weight loss statistics 2025 are not guarantees — they reflect averages across large populations, and individual response depends on many factors including starting weight, adherence, diet, activity level, and overall health. If you are curious whether you may be a candidate, reviewing who qualifies for weight loss medication is a helpful first step.


How 2025 Research Is Reshaping Obesity Treatment Guidelines

The American Academy of Clinical Endocrinology (AACE) and the Obesity Medicine Association (OMA) have both updated their clinical guidelines in recent years to formally include GLP-1 receptor agonists as a first-line pharmacological option for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension or sleep apnea. This represents a substantial shift in how the medical community approaches chronic weight management — moving away from willpower-centric models toward recognizing obesity as a complex, hormone-influenced condition.

2025 research has also expanded the conversation around cardiovascular benefits. The SELECT trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by approximately 20% in overweight and obese adults with established cardiovascular disease — regardless of whether they had diabetes. These findings have further accelerated prescribing trends and are influencing how telehealth platforms like EdenRx structure weight loss programs with comprehensive, clinically grounded protocols.


Accessibility and Cost: What Patients Are Actually Experiencing in 2025

One of the most significant developments in the GLP-1 landscape in 2025 is the evolving conversation around accessibility and cost. Branded GLP-1 medications can carry monthly price tags exceeding $1,000 without insurance coverage, creating a substantial barrier for many patients. However, compounded formulations — where legally and clinically appropriate — and emerging generic pathways are beginning to broaden access for a wider patient population.

EdenRx was designed with this accessibility challenge in mind. Transparent pricing and a streamlined online intake process mean that patients in Florida and New York do not need to navigate complex referral systems or wait months for an appointment. The online weight loss consultation model allows a licensed provider to review your health profile and potentially recommend a personalized plan — all without requiring an in-person visit. Costs and coverage will vary based on individual circumstances, and EdenRx encourages patients to review all program details before enrolling.


Long-Term Outcomes: What Happens After GLP-1 Therapy?

One of the most actively studied questions in 2025 is what happens to patients who discontinue GLP-1 medications after achieving meaningful weight loss. The STEP 4 extension trial observed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year, reinforcing the understanding that GLP-1 therapy may be most effective as part of a sustained, long-term management strategy rather than a short-term fix.

This has important implications for how programs should be structured. Responsible telehealth providers are increasingly emphasizing ongoing monitoring, behavioral support, and regular provider check-ins as essential components of care. At EdenRx, the approach is built around continuity — not just an initial prescription. Patients who complete a free assessment receive a comprehensive review from a licensed provider who evaluates not just whether they may qualify, but how a program can be designed to support lasting progress. Results will always vary from person to person.


Why Provider Review Matters

With GLP-1 prescriptions rising sharply across telehealth platforms, the quality of the prescribing process has become a critical differentiator. Not every platform that offers GLP-1 medications conducts a meaningful clinical review — some rely on automated questionnaires with minimal provider oversight. This approach may put patients at risk, particularly those with contraindications such as a personal or family history of medullary thyroid carcinoma, pancreatitis, or certain gastrointestinal conditions.

EdenRx's model is built around provider-reviewed care. Every patient who submits an assessment is reviewed by a licensed medical professional who evaluates their full health picture before any recommendation is made. This is not a rubber-stamp process — it is a genuine clinical review designed to prioritize patient safety alongside weight loss goals. Built from Eden Med Spa — real patients, real treatments. That foundation means EdenRx brings the standards of in-person medical practice to the convenience of telehealth, serving eligible patients across Florida and New York.


Thinking about GLP-1 therapy? See if you may be eligible — Start Your Free Assessment. Provider-reviewed. No payment required to begin.


Frequently Asked Questions

What do the latest GLP-1 weight loss statistics 2025 show?

Clinical trial data published through 2025 suggests that GLP-1 receptor agonists may support average body weight reductions of 15–22% over 68–72 weeks in eligible adults. These are clinical averages — individual results vary significantly based on health status, lifestyle, adherence, and other factors.

Who may qualify for GLP-1 weight loss medication?

Generally, adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition, may potentially be considered candidates. A licensed provider must evaluate your individual health profile to determine eligibility. You can learn more at who qualifies for weight loss medication.

Is GLP-1 therapy available through telehealth in Florida and New York?

Yes — EdenRx currently serves eligible patients in Florida and New York through a provider-reviewed telehealth model. Patients complete an online assessment, which is reviewed by a licensed provider who determines whether a GLP-1 program may be appropriate. Availability is subject to individual clinical review.

What is the difference between semaglutide and tirzepatide?

Both are GLP-1 receptor agonists, but tirzepatide is a dual GIP/GLP-1 agonist, meaning it activates two hormone pathways rather than one. Some 2025 trial data suggests tirzepatide may produce modestly greater average weight loss, though both medications have demonstrated meaningful results in clinical settings. A provider will help determine which option, if any, may be appropriate for you.

Does weight come back after stopping GLP-1 medications?

Research, including the STEP 4 extension trial, indicates that a substantial portion of lost weight may return after discontinuing GLP-1 therapy without ongoing lifestyle and behavioral support. This is why EdenRx emphasizes a structured, long-term program approach rather than short-term prescribing alone.

How do I get started with EdenRx?

You can begin with a free, no-obligation assessment at /assessment. A licensed provider will review your submission and, if you may be eligible, discuss program options tailored to your health profile. No payment is required to start, and full pricing details are available on the site.


Conclusion

The GLP-1 weight loss statistics 2025 represent some of the most encouraging data in the history of obesity medicine — but data alone does not determine what is right for any individual patient. The most important step is a thorough, honest clinical evaluation that considers your unique health history, goals, and circumstances. For eligible adults in Florida and New York, EdenRx offers a provider-reviewed path to exploring whether GLP-1 therapy may be part of your weight management journey.

Transparency, safety, and clinical integrity are at the core of how EdenRx operates — because lasting results require more than a prescription. They require a plan, a provider, and a partnership.

Take the first step today. Start Your Free Assessment — reviewed by a licensed provider, no payment required to begin. Explore all programs or review pricing to learn more.

See if you qualify in 60 seconds

Provider-reviewed · Only pay if approved · Cancel anytime

Start Free Medical Assessment
No Payment Required Response Within 24h Built from Eden Med Spa
GLP-1 weight loss semaglutide tirzepatide obesity medicine telehealth Florida New York 2025 research EdenRx

Share This Article

Share Text

2025 GLP-1 research shows up to 22% average weight loss in eligible adults. See what the data means for you — and whether you may qualify for a provider-reviewed program. #GLP1 #WeightLoss #EdenRx

No payment required to start — get up to $50 off your first month.

A licensed provider reviews every case. Only pay if approved. Cancel anytime.

Start Free Medical Assessment
No Payment Required Response Within 24h Built from Eden Med Spa
Live Activity
131 people online now
1,076 visits today
10 orders shipped today
HIPAA Secure